Drugs / CADI-05
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07455032 | Apr 2026 → Nov 2027 expected | head and neck squamous cell carcinoma | Fox Chase Cancer Center | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00675727 | Dec 2006 → Dec 2010 | melanoma | Cadila Pharnmaceuticals | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CADI-05 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07455032 ↗ |
| Modality | Vaccine | “This study examines the safety of treating patients with advanced stage melanoma with the vaccine CADI-05.” NCT00675727 ↗ |